Medical medium peanut allergy claims have gained online traction, but understanding what the evidence actually says is essential for safe management. Peanut allergy is one of the UK's most common food allergies, affecting around 2% of children and up to 1% of adults, and can cause life-threatening anaphylaxis. Diagnosis and treatment are guided by NHS, NICE, and BSACI frameworks — not wellness brands or unvalidated protocols. This article explains how peanut allergy is diagnosed and managed in the UK, what licensed treatments are available, and why evidence-based care must always take precedence over alternative approaches.

What Is Peanut Allergy and How Is It Diagnosed in the UK?

Peanut allergy is an IgE-mediated immune reaction diagnosed by an NHS allergy specialist using skin prick testing, specific IgE blood tests, and oral food challenge, in line with NICE guideline CG116 and BSACI guidance.

Peanut allergy is one of the most common food allergies in the UK, affecting approximately 2% of children and an estimated 0.5–1% of adults. It is an immune-mediated reaction in which the body's immune system mistakenly identifies peanut proteins — particularly Ara h 1, Ara h 2, and Ara h 3 — as harmful. This triggers the production of immunoglobulin E (IgE) antibodies, leading to the release of histamine and other inflammatory mediators. Reactions can range from mild symptoms such as hives and itching to severe, life-threatening anaphylaxis.

In the UK, diagnosis is carried out by an NHS allergy specialist or immunologist following a structured clinical assessment, in line with NICE guideline CG116 (Food allergy in under 19s) and BSACI guidance on peanut and tree nut allergy. The diagnostic process may include:

• Detailed clinical history, including the nature, timing, and severity of previous reactions

• Skin prick testing (SPT), which measures the immediate hypersensitivity response to peanut allergen extracts

• Specific IgE blood tests, measuring antibodies to whole peanut or individual peanut components

• Oral food challenge (OFC), considered the gold standard for diagnosis, conducted under medical supervision in a controlled clinical setting

Component-resolved diagnostics (CRD), which test for specific peanut proteins such as Ara h 2, can improve diagnostic accuracy for clinical peanut allergy and assist with risk stratification. However, they cannot reliably predict the severity of a reaction in an individual patient, and results must always be interpreted within the context of a full specialist-led clinical assessment.

NICE CG116 and the BSACI recommend that diagnosis should always be confirmed by a qualified healthcare professional. Self-diagnosis based on unvalidated tests — such as IgG food antibody testing or hair analysis — or non-clinical sources can lead to unnecessary dietary restriction or, conversely, dangerous under-management of a genuine allergy.

NHS and NICE Guidance on Managing Peanut Allergy

NHS and NICE guidance centres on strict allergen avoidance, prescription of adrenaline auto-injectors for those at anaphylaxis risk, a written emergency action plan, and regular specialist review.

The NHS and NICE provide clear, evidence-based frameworks for the management of peanut allergy in both children and adults, set out in NICE guideline CG116 and NICE Quality Standard QS118 (Food allergy). Central to this guidance is the principle of strict allergen avoidance combined with preparedness for accidental exposure.

Individuals diagnosed with peanut allergy should be assessed for their individual risk of anaphylaxis. Those at risk — including those with a history of anaphylaxis, co-existing asthma, or where avoidance is particularly difficult — should be prescribed adrenaline auto-injectors (AAIs), such as EpiPen or Jext, as a first-line emergency treatment. Patients prescribed AAIs should carry two in-date devices at all times and ensure that they, and those around them, are trained in their use. Guidance on AAI prescribing and action plans is available from the BSACI and Anaphylaxis UK.

A structured allergy management plan, in line with NICE QS118 and Resuscitation Council UK guidance, should include:

• A written emergency action plan detailing symptoms and stepwise treatment

• Education for patients, parents, and carers on allergen avoidance and AAI use

• Regular review by an allergy specialist, particularly for children as their risk profile may change with age

• Referral to a dietitian where dietary restriction may affect nutritional intake

The NHS also supports the use of medical alert identification (such as MedicAlert bracelets) and encourages patients to inform schools, workplaces, and restaurants of their allergy. Labelling legislation in the UK, governed by the Food Standards Agency (FSA) following the introduction of Natasha's Law in 2021, requires pre-packed food for direct sale to carry full ingredient labelling, including the 14 major allergens. Healthcare professionals play a key role in ensuring patients understand how to interpret food labels and navigate eating outside the home safely.

If you suspect a reaction to a medicine or medical device, this should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app).

Evidence-Based Treatments Available for Peanut Allergy

Palforzia is the only MHRA-licensed oral immunotherapy for peanut allergy in the UK, available for patients aged 4–17; anaphylaxis and eosinophilic oesophagitis are recognised adverse events requiring specialist supervision.

Until relatively recently, strict avoidance was the only management strategy available for peanut allergy. However, significant advances in immunotherapy have changed the treatment landscape. Oral immunotherapy (OIT) involves the gradual, supervised introduction of increasing doses of peanut protein to desensitise the immune system over time. Clinical trials, including the landmark PALISADE study, have demonstrated that OIT can meaningfully raise the threshold at which reactions occur, reducing the risk of severe reactions from accidental exposure.

Palforzia (AR101) is a standardised oral immunotherapy product licensed by the MHRA for the treatment of peanut allergy in patients aged 4 to 17 years; treatment may be continued in patients who reach adulthood if started before the age of 18. It is the first licensed pharmaceutical treatment specifically for peanut allergy in the UK. Palforzia is administered in three phases — initial dose escalation, up-dosing, and maintenance — all under medical supervision in a specialist centre.

Patients and carers should be aware that anaphylaxis is a recognised adverse event during OIT, including with Palforzia, and is not uncommon. Other adverse reactions include gastrointestinal symptoms (such as abdominal pain, nausea, and vomiting), urticaria, and — with longer-term use — eosinophilic oesophagitis (EoE). Key contraindications and cautions include uncontrolled or severe asthma, a history of eosinophilic oesophagitis or other eosinophilic gastrointestinal disease, and active systemic allergic reactions. Doses should be withheld during intercurrent illness, after strenuous exercise, or when asthma is poorly controlled. Patients undergoing OIT must continue allergen avoidance and carry two in-date AAIs at all times. Full prescribing information is available in the MHRA-approved Summary of Product Characteristics (SmPC) for Palforzia.

Experiencing these side effects? Our pharmacists can help you navigate them →

As of the time of writing, NICE has not recommended Palforzia for routine NHS commissioning in England; access may therefore be limited to specialist centres or private provision. Patients interested in OIT should discuss eligibility and access with their allergy specialist.

Other approaches under investigation include:

• Sublingual immunotherapy (SLIT), where small amounts of allergen are placed under the tongue — not currently licensed for peanut allergy in the UK

• Epicutaneous immunotherapy (EPIT), delivered via a skin patch (e.g., Viaskin Peanut) — currently investigational and not licensed in the UK

• Biologic therapies, such as omalizumab (an anti-IgE monoclonal antibody), being studied as an adjunct to OIT — use for food allergy is off-label in the UK and remains under investigation

These treatments aim to achieve desensitisation, not a cure, and ongoing maintenance dosing is typically required. Suspected adverse reactions to any of these treatments should be reported via the MHRA Yellow Card Scheme.

What the Research Says About Alternative Approaches

There is no scientific evidence that medical medium protocols, viral infection theories, or dietary supplements can treat or cure peanut allergy; unvalidated approaches risk serious harm including fatal anaphylaxis.

The term 'medical medium' refers to a popular wellness brand and book series by Anthony William, which promotes the idea that many chronic health conditions — including food allergies — are caused by viral infections, particularly the Epstein-Barr virus, and can be addressed through specific dietary protocols, supplements, and detoxification practices. It is important to state clearly that there is no scientific or clinical evidence to support these claims in relation to peanut allergy, and they are not endorsed by any UK regulatory or medical body, including the NHS, NICE, MHRA, or BSACI.

Peanut allergy is a well-characterised IgE-mediated immune response. Its mechanisms are understood at a molecular level, and its management is guided by robust clinical research. No peer-reviewed evidence supports the notion that viral infections cause peanut allergy or that dietary supplements can reverse or cure it. Patients who delay or abandon evidence-based management in favour of unvalidated approaches risk serious harm, including fatal anaphylaxis.

Patients should also be aware that unvalidated tests — such as IgG food antibody testing, hair analysis, or kinesiology — are not recommended by the NHS or BSACI for the diagnosis or management of food allergy, and may lead to unnecessary dietary restriction or false reassurance.

This does not mean that diet and lifestyle are irrelevant to overall health. A balanced, nutritious diet is beneficial for immune health generally, and robust evidence from the LEAP (Learning Early About Peanut Allergy) study suggests that early introduction of peanut-containing foods in infancy may reduce the risk of developing peanut allergy. However, these findings relate to prevention, not treatment, and should be implemented only under appropriate clinical guidance. Patients curious about complementary approaches should always discuss these with their GP or allergy specialist before making any changes to their management plan.

When to Seek Medical Advice and Emergency Care

Anaphylaxis requires immediate adrenaline injection and a 999 call; all patients at risk should carry two in-date AAIs and seek hospital observation after any suspected anaphylactic reaction.

Knowing when to seek urgent medical help is a critical component of living safely with peanut allergy. Anaphylaxis is a medical emergency and requires immediate treatment with adrenaline, followed by a 999 call and transfer to hospital. Symptoms of anaphylaxis may include:

• Throat tightening, hoarseness, or difficulty swallowing

• Difficulty breathing, wheezing, or stridor

• Rapid or weak pulse, dizziness, or collapse

• Widespread urticaria (hives), flushing, or swelling of the face and lips

• Nausea, vomiting, or abdominal pain in combination with other symptoms

If an adrenaline auto-injector is available and anaphylaxis is suspected, it should be administered immediately into the outer thigh, even through clothing. If symptoms do not improve or worsen, a second AAI dose should be given after 5 minutes. Call 999 without delay. All patients with peanut allergy at risk of anaphylaxis should carry two in-date AAIs at all times.

Following administration of adrenaline, position the patient appropriately whilst awaiting emergency services:

• Lie flat with legs raised if they feel faint or have collapsed

• Sit up if breathing is difficult

• Pregnant individuals should lie on their left side

• Do not allow the patient to stand or walk

All patients who have experienced suspected anaphylaxis require hospital observation, even if symptoms appear to resolve, as biphasic reactions can occur. This guidance is consistent with Resuscitation Council UK recommendations on the emergency treatment of anaphylaxis.

Beyond emergencies, patients should seek routine medical advice if:

• They have not yet been formally assessed by an allergy specialist

• Their symptoms appear to be worsening or changing over time

• They are considering pregnancy, as allergy management may need review

• A child with peanut allergy is approaching school age and requires an individual healthcare plan

• They are interested in immunotherapy and wish to discuss eligibility

GPs can refer patients to NHS allergy services, and the BSACI website provides a directory of accredited allergy clinics across the UK.

Living Safely with Peanut Allergy: Practical UK Advice

Safe daily management includes carrying two in-date AAIs, reading food labels carefully under FSA guidance, informing restaurant staff, and ensuring schools and workplaces have an accessible emergency plan.

Managing peanut allergy on a day-to-day basis requires vigilance, preparation, and confidence. With the right knowledge and support, most people with peanut allergy lead full, active lives. The following practical measures are recommended by the NHS and allergy specialists:

Adrenaline auto-injectors:

• Carry two in-date AAIs at all times — check expiry dates regularly and replace promptly when due

• Ensure you, your family members, and relevant contacts are trained in how to use your AAI correctly

• Review your written emergency action plan annually or after any allergic reaction

Food labelling and shopping:

• Always read ingredient labels carefully, even for familiar products, as recipes can change

• Look for 'may contain peanuts' or 'made in a facility that handles peanuts' advisory warnings, which indicate a risk of cross-contamination; the FSA provides guidance on Precautionary Allergen Labelling (PAL) to help interpret these statements

• Use the FSA's allergen guidance and supermarket allergen tools where available

Eating out:

• Inform restaurant staff of your allergy before ordering — do not assume dishes are safe

• Ask about preparation methods and cross-contamination risks in the kitchen

• Consider using allergy alert cards, available from Allergy UK, to communicate your needs clearly

At school and work:

• Ensure teachers, colleagues, and relevant staff are aware of the allergy and know how to use an AAI

• Keep a spare AAI in a clearly labelled, accessible location — UK schools in England are permitted to hold spare AAIs for emergency use in line with Department for Education (DfE) guidance on supporting pupils with medical conditions

• Children with peanut allergy should have an individual healthcare plan in place before starting school

Emotional and psychological wellbeing: Living with a potentially life-threatening allergy can cause significant anxiety, particularly in parents of affected children. The NHS and organisations such as Allergy UK and Anaphylaxis UK offer support resources, helplines, and community networks. Psychological support, including cognitive behavioural therapy (CBT), may be appropriate for those experiencing allergy-related anxiety.

Staying connected with your allergy team, keeping up to date with your prescriptions, and maintaining an informed, proactive approach to daily management are the most effective ways to stay safe. If you experience a suspected reaction to a medicine or medical device, report it via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app).

Frequently Asked Questions